SAGE Therapeutics Received its Third Buy in a Row

After BMO Capital and Needham gave SAGE Therapeutics (NASDAQ: SAGE) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa upgraded SAGE Therapeutics to Buy today and set a price target of $225. The company’s shares closed yesterday at $163.09.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 23.5% and a 53.6% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Arbutus Biopharma Corporation.

Currently, the analyst consensus on SAGE Therapeutics is Strong Buy and the average price target is $206.71, representing a 26.7% upside.

In a report issued on May 7, Cowen & Co. also maintained a Buy rating on the stock with a $207 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $195.97 and a one-year low of $59.57. Currently, SAGE Therapeutics has an average volume of 465.4K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders.